Trial Outcomes & Findings for Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (NCT NCT03737643)

Last Updated: 2026-07-07

Results Overview

To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE3

Target enrollment

1407 participants

Primary outcome timeframe

At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

Results posted on

2026-07-07

Participant Flow

Overall, 1407 patients were randomised into the study. Global Cohort: 1502 patients screened across 179 sites in 20 countries. 1130 were randomised in the Non-tBRCAm cohort and 154 allocated to the tBRCAm cohort. China Cohort: 134 patients screened across 29 sites; 124 were randomized. 1 patient in the China cohort was randomised prior to Global recruitment closure and hence included in both the Global and China cohort summaries. No patients in the tBRCAm cohort were enrolled from China

This study planned to allocate/randomise approximately 1254 patients with newly-diagnosed advanced ovarian cancer patients. In addition, a China cohort of approximately 120 non-tBRCAm patients with newly-diagnosed advanced ovarian cancer patients was planned to be randomised.

Participant milestones

Participant milestones
Measure	Global Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC + Durvalumab Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Global tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC + Durvalumab Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Overall Study STARTED	378	374	378	154	40	43	41
Overall Study COMPLETED	153	160	172	100	26	31	34
Overall Study NOT COMPLETED	225	214	206	54	14	12	7

Reasons for withdrawal

Reasons for withdrawal
Measure	Global Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC + Durvalumab Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Global tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC + Durvalumab Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC + Durvalumab + Olaparib Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Overall Study Death	201	196	186	46	14	11	7
Overall Study Withdrawal by Subject	22	17	20	7	0	1	0
Overall Study Pre-mature site closure and screen failure,	2	1	0	1	0	0	0

Baseline Characteristics

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC + Durvalumab n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC + Durvalumab + Olaparib n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Global tBRCAm: SoC + Durvalumab + Olaparib n=154 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC + Durvalumab n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC + Durvalumab + Olaparib n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Total n=1408 Participants Total of all reporting groups
Ethnicity (NIH/OMB) Hispanic or Latino	29 Participants n=20 Participants	20 Participants n=20 Participants	25 Participants n=40 Participants	5 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	79 Participants n=6 Participants
Age, Continuous	58.7 Years STANDARD_DEVIATION 9.9 • n=20 Participants	58.5 Years STANDARD_DEVIATION 10.8 • n=20 Participants	60.2 Years STANDARD_DEVIATION 10.4 • n=40 Participants	55.7 Years STANDARD_DEVIATION 10.3 • n=5 Participants	58.8 Years STANDARD_DEVIATION 8.6 • n=9 Participants	52.8 Years STANDARD_DEVIATION 8.7 • n=6 Participants	53.9 Years STANDARD_DEVIATION 9.4 • n=6 Participants	58.4 Years STANDARD_DEVIATION 10.4 • n=6 Participants
Age, Customized >=65	110 Participants n=20 Participants	126 Participants n=20 Participants	135 Participants n=40 Participants	37 Participants n=5 Participants	10 Participants n=9 Participants	4 Participants n=6 Participants	5 Participants n=6 Participants	427 Participants n=6 Participants
Age, Customized <65	268 Participants n=20 Participants	248 Participants n=20 Participants	243 Participants n=40 Participants	117 Participants n=5 Participants	30 Participants n=9 Participants	39 Participants n=6 Participants	36 Participants n=6 Participants	981 Participants n=6 Participants
Sex/Gender, Customized Female	378 Participants n=20 Participants	374 Participants n=20 Participants	378 Participants n=40 Participants	154 Participants n=5 Participants	40 Participants n=9 Participants	43 Participants n=6 Participants	41 Participants n=6 Participants	1408 Participants n=6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	345 Participants n=20 Participants	347 Participants n=20 Participants	346 Participants n=40 Participants	149 Participants n=5 Participants	40 Participants n=9 Participants	43 Participants n=6 Participants	41 Participants n=6 Participants	1311 Participants n=6 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	4 Participants n=20 Participants	7 Participants n=20 Participants	7 Participants n=40 Participants	0 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	18 Participants n=6 Participants
Race/Ethnicity, Customized AMERICAN INDIAN OR ALASKA NATIVE	4 Participants n=20 Participants	4 Participants n=20 Participants	1 Participants n=40 Participants	1 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	10 Participants n=6 Participants
Race/Ethnicity, Customized ASIAN	55 Participants n=20 Participants	52 Participants n=20 Participants	47 Participants n=40 Participants	45 Participants n=5 Participants	40 Participants n=9 Participants	43 Participants n=6 Participants	41 Participants n=6 Participants	323 Participants n=6 Participants
Race/Ethnicity, Customized BLACK OR AFRICAN AMERICAN	3 Participants n=20 Participants	3 Participants n=20 Participants	4 Participants n=40 Participants	1 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	11 Participants n=6 Participants
Race/Ethnicity, Customized MISSING	1 Participants n=20 Participants	6 Participants n=20 Participants	1 Participants n=40 Participants	0 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	8 Participants n=6 Participants
Race/Ethnicity, Customized NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0 Participants n=20 Participants	0 Participants n=20 Participants	0 Participants n=40 Participants	0 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants
Race/Ethnicity, Customized OTHER	23 Participants n=20 Participants	16 Participants n=20 Participants	19 Participants n=40 Participants	1 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	59 Participants n=6 Participants
Race/Ethnicity, Customized WHITE	292 Participants n=20 Participants	293 Participants n=20 Participants	306 Participants n=40 Participants	106 Participants n=5 Participants	0 Participants n=9 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	997 Participants n=6 Participants

PRIMARY outcome

Timeframe: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

Population: Full Analysis Set (FAS) consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 17 June 2021). China FAS includes all patients who were randomised at sites in China.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=40 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=41 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set	24.2 Months Interval 22.7 to 26.8	17.4 Months Interval 11.7 to 26.4	26.8 Months Interval 23.5 to Insufficient number of events to estimate upper limit.	19.3 Months Interval 17.9 to 20.3	—	—	—

PRIMARY outcome

Timeframe: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=20 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=28 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)	37.3 Months Interval 29.8 to Insufficient number of events to estimate upper limit.	15.6 Months Interval 9.3 to 23.9	26.8 Months Interval 23.5 to Insufficient number of events to estimate upper limit.	23 Months Interval 21.2 to 24.8	—	—	—

SECONDARY outcome

Timeframe: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.

To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=40 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=43 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set	20.6 Months Interval 18.7 to 22.5	17.4 Months Interval 11.7 to 26.4	21.7 Months Interval 12.4 to Insufficient number of events to estimate upper limit.	19.3 Months Interval 17.9 to 20.4	—	—	—

SECONDARY outcome

Timeframe: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Overall Survival - Full Analysis Set	48.5 Months Interval 43.6 to 59.0	50.5 Months Interval 45.2 to 65.1	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	49.6 Months Interval 45.8 to 57.8	43.2 Months Interval 34.1 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=20 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=28 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Overall Survival - (Full Analysis Set, HRD-positive)	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	66.8 Months Interval 60.9 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Timeframe: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.

To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set	34.6 Months Interval 30.2 to 37.7	36.9 Months Interval 32.7 to 41.1	27.5 Months Interval 19.8 to Insufficient number of events to estimate upper limit.	32.6 Months Interval 30.7 to 35.4	28.8 Months Interval 22.6 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=20 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=28 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)	51.3 Months Interval 40.8 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	42.4 Months Interval 38.8 to 58.9	34.1 Months Interval 22.2 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Timeframe: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)

Population: All participants with measurable disease at baseline were included in the analysis. Full Analysis Set (FAS) consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 17 June 2021). China FAS includes all patients who were randomised at sites in China.

To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1: 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=288 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=296 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=117 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=296 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=26 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O n=27 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)	68.1 Percentage of participants	74.3 Percentage of participants	72.6 Percentage of participants	70.3 Percentage of participants	57.7 Percentage of participants	56.7 Percentage of participants	66.7 Percentage of participants

SECONDARY outcome

To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator. This was prespecified to be assessed only in the non-tBRCAm cohort.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=107 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=103 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=16 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=108 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=21 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=18 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)	73.8 Percentage of participants	85.4 Percentage of participants	56.3 Percentage of participants	82.4 Percentage of participants	71.4 Percentage of participants	66.7 Percentage of participants	—

SECONDARY outcome

Population: All participants with confirmed response were included in the analysis. Full Analysis Set (FAS) consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 17 June 2021). China FAS includes all patients who were randomised at sites in China.

To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in the Global patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=196 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=220 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=154 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=208 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)	15.9 Months Interval 8.4 to 28.3	22.3 Months Interval 12.1 to Insufficient DoR events to estimate upper confidence limit.	NA Months Interval 24.9 to Median and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	16.4 Months Interval 8.3 to 23.8	—	—	—

SECONDARY outcome

Timeframe: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=79 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=88 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=89 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)	19.3 Months Interval 11.5 to 34.5	31.3 Months Interval 18.4 to Insufficient DoR events to estimate upper confidence limit.	—	19.4 Months Interval 12.5 to 47.8	—	—	—

SECONDARY outcome

Timeframe: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.

To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to First Subsequent Therapy (TFST) - Full Analysis Set	21.9 Months Interval 19.8 to 23.4	26.3 Months Interval 24.2 to 29.5	19.0 Months Interval 12.4 to 27.6	21.6 Months Interval 20.1 to 23.4	21.7 Months Interval 15.6 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=20 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=28 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)	29.0 Months Interval 25.1 to 39.2	41.4 Months Interval 33.2 to 59.2	17.9 Months Interval 11.7 to Insufficient number of events to estimate upper limit.	25.8 Months Interval 23.5 to 30.9	34.1 Months Interval 16.8 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Second Subsequent Therapy (TSST) - Full Analysis Set	34.9 Months Interval 31.8 to 37.8	38.5 Months Interval 34.6 to 42.1	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	33.1 Months Interval 31.6 to 36.6	30.6 Months Interval 22.2 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=20 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=28 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)	48.4 Months Interval 41.8 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	46.8 Months Interval 39.5 to 60.0	34.1 Months Interval 22.2 to Insufficient number of events to estimate upper limit.	NA Months Median, lower and upper limits of the 95% Confidence Interval not reached due to insufficient number of participants with events	—

SECONDARY outcome

Timeframe: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)

To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=43 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=41 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Treatment Discontinuation (TDT) - Full Analysis Set	17.5 Months Interval 15.2 to 19.4	20.4 Months Interval 18.5 to 21.7	14.8 Months Interval 10.4 to 23.0	18.4 Months Interval 17.1 to 19.7	14.5 Months Interval 9.0 to 22.4	22.0 Months Interval 15.4 to 26.1	—

SECONDARY outcome

Timeframe: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=20 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D n=30 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O n=28 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)	22.3 Months Interval 19.4 to 24.3	24.7 Months Interval 21.9 to 27.5	15.7 Months Interval 9.2 to 24.0	22.0 Months Interval 20.5 to 24.9	20.0 Months Interval 11.8 to Insufficient number of events to estimate upper limit.	21.8 Months Interval 14.6 to 26.1	—

SECONDARY outcome

Timeframe: Assessed at week 96.

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set	3.3 Score on a scale Standard Error 1.25	3.0 Score on a scale Standard Error 1.31	—	6.3 Score on a scale Standard Error 1.30	—	—	—

SECONDARY outcome

Timeframe: Assessed at week 96.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)	4.9 Score on a scale Standard Error 1.88	7.6 Score on a scale Standard Error 1.61	—	9.8 Score on a scale Standard Error 1.53	—	—	—

SECONDARY outcome

Timeframe: Assessed at week 96.

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=374 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=378 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=378 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set	3.8 Score on a scale Standard Error 1.33	4.6 Score on a scale Standard Error 1.19	—	6.3 Score on a scale Standard Error 1.23	—	—	—

SECONDARY outcome

Timeframe: Assessed at week 96

To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=148 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=140 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=143 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)	6.3 Score on a scale Standard Error 1.97	7.0 Score on a scale Standard Error 1.64	—	8.5 Score on a scale Standard Error 1.75	—	—	—

SECONDARY outcome

Timeframe: Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.

Population: The PK analysis set comprises of all evaluable patients (a subset of those in the full analysis set) dosed with SoC + durvalumab or SoC + durvalumab + olaparib and providing at least one post-dose analysable concentration of durvalumab and/or olaparib.

To characterize the PK of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=92 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=71 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Day 85, pre-dose	207988.974 μg/mL Geometric Coefficient of Variation 30.1	—	—	218376.482 μg/mL Geometric Coefficient of Variation 40.8	—	—	—
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Day 148, pre-dose	252257.020 μg/mL Geometric Coefficient of Variation 39.9	—	—	237360.027 μg/mL Geometric Coefficient of Variation 36.8	—	—	—
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Follow-up (3 months after last dose of durvalumab.)	25776.441 μg/mL Geometric Coefficient of Variation 218.4	—	—	38355.597 μg/mL Geometric Coefficient of Variation 112.3	—	—	—

SECONDARY outcome

Timeframe: Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)

Population: The PK analysis set comprises of all evaluable patients (a subset of those in the full analysis set) dosed with SoC + durvalumab + olaparib and providing at least one post-dose analysable concentration of olaparib.

To determine olaparib plasma concentrations via sparse sampling for population PK analyses. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=92 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Day 148, 1-3 hours	—	—	—	5.8563 μg/mL Geometric Coefficient of Variation 47.7	—	—	—
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Day 148, 3-6 hours	—	—	—	4.2425 μg/mL Geometric Coefficient of Variation 38.4	—	—	—
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set) Day 148, 6-12 hours	—	—	—	2.5059 μg/mL Geometric Coefficient of Variation 44.2	—	—	—

SECONDARY outcome

Timeframe: Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab

Population: The ADA evaluable subjects are patients in the Safety Analysis Set who received at least 1 dose of durvalumab and have non-missing baseline ADA and at least 1 post-baseline ADA result.

To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.

Outcome measures

Outcome measures
Measure	Global Non-tBRCAm: SoC+D n=74 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC+D+O n=132 Participants Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC n=58 Participants Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC+D Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC+D+O Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) ADA positive at any visit (ADA Prevalence)	2 Number of participants	6 Number of participants	—	4 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Transiently positive	0 Number of participants	1 Number of participants	—	1 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Treatment-emergent ADA-positive (ADA incidence)	0 Number of participants	1 Number of participants	—	1 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Treatment-boosted ADA	0 Number of participants	0 Number of participants	—	0 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Treatment-induced ADA (Positive Post-baseline only)	0 Number of participants	1 Number of participants	—	1 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) ADA positive at baseline only	2 Number of participants	5 Number of participants	—	3 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) ADA Positive Post-baseline and Positive at Baseline	0 Number of participants	0 Number of participants	—	0 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Persistently positive	0 Number of participants	0 Number of participants	—	0 Number of participants	—	—	—
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set) Neutralising antibody positive at any visit	0 Number of participants	0 Number of participants	—	0 Number of participants	—	—	—

Adverse Events

Global Non-tBRCAm: SoC

Serious events: 132 serious events

Other events: 369 other events

Deaths: 205 deaths

Global Non-tBRCAm: SoC + Durvalumab

Serious events: 165 serious events

Other events: 367 other events

Deaths: 200 deaths

Global Non-tBRCAm: SoC + Durvalumab + Olaparib

Serious events: 152 serious events

Other events: 372 other events

Deaths: 193 deaths

Global tBRCAm: SoC + Durvalumab + Olaparib

Serious events: 74 serious events

Other events: 151 other events

Deaths: 47 deaths

China Non-tBRCAm: SoC

Serious events: 19 serious events

Other events: 40 other events

Deaths: 14 deaths

China Non-tBRCAm: SoC + Durvalumab

Serious events: 17 serious events

Other events: 43 other events

Deaths: 11 deaths

China Non-tBRCAm: SoC + Durvalumab + Olaparib

Serious events: 22 serious events

Other events: 41 other events

Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure	Global Non-tBRCAm: SoC n=376 participants at risk Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC + Durvalumab n=373 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC + Durvalumab + Olaparib n=378 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Global tBRCAm: SoC + Durvalumab + Olaparib n=153 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 participants at risk Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC + Durvalumab n=43 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC + Durvalumab + Olaparib n=41 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Infections and infestations Enterocolitis infectious	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Escherichia urinary tract infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Gastroenteritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Gastroenteritis bacterial	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Atrial fibrillation	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Hepatitis e	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Herpes zoster	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Human anaplasmosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Infected lymphocele	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Infected seroma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Infectious pleural effusion	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Influenza	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Joint abscess	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Anaemia	1.3% 5/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.2% 12/378 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.2% 5/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Atrial flutter	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pelvic abscess	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Peritonitis	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Peritonitis bacterial	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pneumonia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pneumonia cytomegaloviral	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Post procedural infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Postoperative wound infection	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Psoas abscess	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pyelonephritis acute	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Atrial thrombosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Respiratory tract infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Sepsis	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Septic shock	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Sinusitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Staphylococcal bacteraemia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Staphylococcal infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Intestinal perforation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Intra-abdominal haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Large intestine perforation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Mechanical ileus	0.80% 3/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Melaena	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Nausea	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Pancreatitis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Myelosuppression	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Proctitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Rectal discharge	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Small intestinal obstruction	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Small intestinal perforation	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Stomatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Subileus	0.80% 3/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/378 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Superior mesenteric artery syndrome	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Neutropenia	1.3% 5/376 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Umbilical hernia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Vomiting	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Administration site extravasation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Asthenia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Dehiscence	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Extravasation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Fatigue	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders General physical health deterioration	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Hernia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Pancytopenia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Incarcerated hernia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Multiple organ dysfunction syndrome	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Non-cardiac chest pain	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Pain	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Performance status decreased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Pyrexia	1.3% 5/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 10/378 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Paratracheal lymphadenopathy	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Autoimmune hepatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Bile duct stone	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Biloma	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Biloma rupture	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Cholecystitis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Cholecystitis acute	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Cholelithiasis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Reticulocytosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatitis acute	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatotoxicity	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Liver disorder	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Suspected drug-induced liver injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Immune system disorders Anaphylactic reaction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Immune system disorders Anaphylactic shock	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Immune system disorders Drug hypersensitivity	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Immune system disorders Sarcoidosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Abdominal abscess	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Abdominal infection	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Abdominal sepsis	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Abscess	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Anal abscess	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Appendicitis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Atypical pneumonia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Bacteraemia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Bacterial infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Acute myocardial infarction	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Bronchitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Bronchopulmonary aspergillosis allergic	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Covid-19	1.1% 4/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.9% 7/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Covid-19 pneumonia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Campylobacter infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Catheter site infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Cellulitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Clostridium difficile colitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Clostridium difficile infection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Angina pectoris	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Device related infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Diverticulitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Endocarditis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Enterocolitis bacterial	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Superinfection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Suspected covid-19	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Upper respiratory tract infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Urinary tract infection	2.1% 8/376 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Atrioventricular block	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Urosepsis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Vulval abscess	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Wound infection	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Wound infection staphylococcal	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Anaemia postoperative	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Anastomotic fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Anastomotic leak	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Diversion colitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Fall	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Cardiac arrest	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Forearm fracture	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Fractured sacrum	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Head injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Incarcerated incisional hernia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Infusion related reaction	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Limb injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Cardiac failure	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Meniscus injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Pneumoconiosis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Post procedural complication	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Postoperative adhesion	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Postoperative ileus	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Postoperative lymphocele	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Amylase increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Postoperative wound complication	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Procedural complication	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Procedural intestinal perforation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Cardiomyopathy	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Scar	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Seroma	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Stoma complication	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Stoma site dermatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Stoma site pain	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Subcutaneous haematoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Tendon rupture	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Coronary artery disease	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Traumatic haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Ulna fracture	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Vaginal cuff dehiscence	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Vulvovaginal injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Wound dehiscence	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Wound evisceration	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Alanine aminotransferase increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Hypertensive heart disease	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood creatinine increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Mitral valve incompetence	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations C-reactive protein increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Hepatic enzyme increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Lipase increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Liver function test increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Mean cell volume increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Neutrophil count decreased	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Norovirus test positive	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Myocardial infarction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Pancreatic enzymes increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Platelet count decreased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations White blood cell count decreased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Cachexia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Aplasia pure red cell	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Palpitations	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Decreased appetite	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Dehydration	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Diabetes mellitus inadequate control	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Electrolyte imbalance	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Pericardial effusion	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hyponatraemia	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Type 1 diabetes mellitus	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Bone pain	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Pericarditis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Fistula discharge	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Immobilisation syndrome	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Immune-mediated arthritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Muscular weakness	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Myositis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Osteoporotic fracture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Presyncope	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Spinal pain	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma pancreas	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cholangiocarcinoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large b-cell lymphoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal perivascular epithelioid cell tumour	0.27% 1/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tubular breast carcinoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Cerebral haemorrhage	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Cerebral infarction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Cerebral ischaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Cerebral venous thrombosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Cerebrovascular accident	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Dizziness	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Encephalitis autoimmune	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Encephalopathy	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Hypoglycaemic unconsciousness	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Immune-mediated neuropathy	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Intracranial aneurysm	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Ischaemic stroke	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Lumbosacral radiculopathy	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Tachycardia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Peripheral motor neuropathy	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Peripheral sensory neuropathy	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Polyneuropathy	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Sciatica	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Secondary cerebellar degeneration	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Syncope	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Transient ischaemic attack	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Ear and labyrinth disorders Hypoacusis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Trigeminal neuralgia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Product Issues Device dislocation	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Acute psychosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Adjustment disorder	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Completed suicide	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Depression	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Mental disorder	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Panic reaction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Psychiatric decompensation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Ear and labyrinth disorders Vertigo	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Suicide attempt	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Acute kidney injury	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Hydronephrosis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Nephritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Nephrolithiasis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Nephrotic syndrome	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Proteinuria	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Renal failure	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Renal impairment	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Ear and labyrinth disorders Vertigo positional	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Tubulointerstitial nephritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Ureteric obstruction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Urinary bladder rupture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Urinary incontinence	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Urinary retention	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Reproductive system and breast disorders Bartholin's cyst	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Reproductive system and breast disorders Female genital tract fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Reproductive system and breast disorders Pelvic fluid collection	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Reproductive system and breast disorders Pelvic haemorrhage	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Autoimmune haemolytic anaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Addison's disease	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Aspiration	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Diaphragmatic rupture	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Organising pneumonia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Adrenal insufficiency	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Cutaneous vasculitis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Rash	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Adrenocorticotropic hormone deficiency	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Toxic skin eruption	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Aortic intramural haematoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Deep vein thrombosis	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Embolism	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Embolism arterial	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Haematoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Hypertension	1.6% 6/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Hypertensive crisis	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Hyperthyroidism	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Lymphocele	1.1% 4/376 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Lymphorrhoea	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Vena cava thrombosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Hypophysitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Hypopituitarism	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Immune-mediated endocrinopathy	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Thyroiditis subacute	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Eye disorders Cataract	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Disseminated intravascular coagulation	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Eye disorders Conjunctival disorder	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Eye disorders Dacryostenosis acquired	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Eye disorders Uveitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal adhesions	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal hernia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal incarcerated hernia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal pain	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Erythroblastosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal wall cyst	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal wall haematoma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Ampullary polyp	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Anal fissure	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Anal fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Ascites	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Colitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Colitis ulcerative	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Colonic fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Febrile neutropenia	2.4% 9/376 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.7% 10/373 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.2% 12/378 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 9/153 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Constipation	1.1% 4/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Diarrhoea	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/378 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Duodenal ulcer	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Dyspepsia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Enteritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Enterocolitis	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Enterocolitis haemorrhagic	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Enterocutaneous fistula	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Enterovesical fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Faecaloma	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Fistula of small intestine	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Flatulence	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Gastric perforation	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Gastric ulcer	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Gastritis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Haematochezia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Immune thrombocytopenia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Haemoperitoneum	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Hernial eventration	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Ileal perforation	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Ileus	1.6% 6/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.79% 3/378 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Immune-mediated enterocolitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Immune-mediated pancreatitis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Inguinal hernia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Intestinal fistula	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Intestinal obstruction	1.1% 4/376 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.

Other adverse events

Other adverse events
Measure	Global Non-tBRCAm: SoC n=376 participants at risk Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	Global Non-tBRCAm: SoC + Durvalumab n=373 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	Global Non-tBRCAm: SoC + Durvalumab + Olaparib n=378 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	Global tBRCAm: SoC + Durvalumab + Olaparib n=153 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.	China Non-tBRCAm: SoC n=40 participants at risk Patients receive saline IV Q3W as a placebo for durvalumab from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months.	China Non-tBRCAm: SoC + Durvalumab n=43 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive placebo tablets, matched to olaparib for up to a total of 24 months	China Non-tBRCAm: SoC + Durvalumab + Olaparib n=41 participants at risk Patients receive durvalumab 1120 mg Q3W from Day 1 of Cycle 2 for up to a total of 35 cycles (24 months) of treatment. At the end of chemotherapy, patients will also receive olaparib tablets, 300 mg twice daily (bd) for up to a total of 24 months.
Blood and lymphatic system disorders Leukopenia	9.0% 34/376 • Number of events 73 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.0% 30/373 • Number of events 37 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.1% 42/378 • Number of events 99 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.1% 20/153 • Number of events 49 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Mouth ulceration	1.1% 4/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Nausea	30.6% 115/376 • Number of events 204 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	29.8% 111/373 • Number of events 192 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	57.9% 219/378 • Number of events 464 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	51.6% 79/153 • Number of events 141 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	37.5% 15/40 • Number of events 35 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	51.2% 22/43 • Number of events 59 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	61.0% 25/41 • Number of events 57 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Stomatitis	8.8% 33/376 • Number of events 43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.6% 47/373 • Number of events 65 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.5% 66/378 • Number of events 91 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 23/153 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Toothache	3.2% 12/376 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.6% 17/373 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.2% 12/378 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.9% 6/153 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.5% 7/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Neutropenia	27.7% 104/376 • Number of events 218 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	27.9% 104/373 • Number of events 177 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	33.9% 128/378 • Number of events 339 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.1% 46/153 • Number of events 128 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Vomiting	16.0% 60/376 • Number of events 101 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.6% 62/373 • Number of events 89 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.7% 97/378 • Number of events 170 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 41/153 • Number of events 75 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.5% 9/40 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.2% 13/43 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	43.9% 18/41 • Number of events 60 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Asthenia	13.3% 50/376 • Number of events 75 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.3% 46/373 • Number of events 67 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.4% 62/378 • Number of events 88 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.1% 17/153 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.0% 10/40 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.3% 10/43 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 11/41 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Chest discomfort	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Fatigue	27.9% 105/376 • Number of events 148 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	27.1% 101/373 • Number of events 153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	35.7% 135/378 • Number of events 224 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.7% 47/153 • Number of events 74 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Influenza like illness	1.9% 7/376 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/378 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.3% 5/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Malaise	1.9% 7/376 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/373 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/378 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.3% 7/43 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 9/41 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Mucosal inflammation	5.6% 21/376 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.8% 18/373 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.9% 26/378 • Number of events 35 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 9/153 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Oedema peripheral	5.3% 20/376 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/373 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.3% 24/378 • Number of events 30 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.3% 5/153 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
General disorders Pyrexia	6.9% 26/376 • Number of events 43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.7% 51/373 • Number of events 77 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.9% 64/378 • Number of events 78 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.6% 27/153 • Number of events 35 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.9% 9/43 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.9% 7/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 4/153 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Thrombocytopenia	11.2% 42/376 • Number of events 65 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.5% 39/373 • Number of events 54 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.9% 60/378 • Number of events 111 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.3% 28/153 • Number of events 51 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Covid-19	7.7% 29/376 • Number of events 29 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.1% 34/373 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.1% 61/378 • Number of events 72 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.8% 12/153 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	35.0% 14/40 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	32.6% 14/43 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	39.0% 16/41 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Coronavirus infection	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Cystitis	4.5% 17/376 • Number of events 27 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 27/373 • Number of events 45 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.3% 24/378 • Number of events 39 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.8% 12/153 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Gingivitis	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Herpes zoster	1.1% 4/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.9% 7/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 9/153 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Influenza	1.1% 4/376 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/373 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Nasopharyngitis	5.3% 20/376 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.7% 25/373 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.3% 24/378 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.1% 17/153 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.2% 5/41 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Blood and lymphatic system disorders Anaemia	27.4% 103/376 • Number of events 156 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	31.9% 119/373 • Number of events 192 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	53.7% 203/378 • Number of events 390 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	54.9% 84/153 • Number of events 178 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	75.0% 30/40 • Number of events 85 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	74.4% 32/43 • Number of events 79 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	82.9% 34/41 • Number of events 156 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Pneumonia	1.1% 4/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Suspected covid-19	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Upper respiratory tract infection	2.1% 8/376 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.7% 10/373 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.8% 18/378 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.9% 6/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.5% 9/40 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.1% 7/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Infections and infestations Urinary tract infection	16.8% 63/376 • Number of events 93 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 56/373 • Number of events 94 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.0% 68/378 • Number of events 128 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.7% 21/153 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.5% 9/40 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.6% 11/43 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	31.7% 13/41 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Injury, poisoning and procedural complications Procedural haemorrhage	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Alanine aminotransferase increased	6.1% 23/376 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 26/373 • Number of events 31 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.2% 31/378 • Number of events 38 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.0% 12/40 • Number of events 32 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	37.2% 16/43 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	46.3% 19/41 • Number of events 56 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Amylase increased	4.5% 17/376 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 22/373 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.2% 16/378 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Aspartate aminotransferase increased	3.5% 13/376 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 28/373 • Number of events 41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.1% 27/378 • Number of events 42 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	47.5% 19/40 • Number of events 44 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	41.9% 18/43 • Number of events 40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	48.8% 20/41 • Number of events 69 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood alkaline phosphatase increased	3.2% 12/376 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.7% 10/373 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.3% 20/378 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 4/153 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.2% 5/41 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood bilirubin increased	1.9% 7/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.53% 2/378 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood creatinine increased	2.9% 11/376 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.3% 16/373 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 35/378 • Number of events 57 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 11/153 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 29 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood fibrinogen increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood glucose increased	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood lactate dehydrogenase increased	1.9% 7/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/373 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 4/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 29 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.3% 7/43 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood thyroid stimulating hormone increased	2.7% 10/376 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/373 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.3% 20/378 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood urea increased	1.1% 4/376 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Blood uric acid increased	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Fibrin d dimer increased	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Gamma-glutamyltransferase increased	3.5% 13/376 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/373 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.9% 11/378 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.0% 8/40 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.3% 10/43 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 11/41 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Lipase increased	4.8% 18/376 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.4% 24/373 • Number of events 29 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.5% 13/153 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Lymphocyte count decreased	1.1% 4/376 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.9% 7/378 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 4/153 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.5% 7/40 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Neutrophil count decreased	15.7% 59/376 • Number of events 103 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 56/373 • Number of events 112 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.7% 67/378 • Number of events 148 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.7% 24/153 • Number of events 47 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	67.5% 27/40 • Number of events 99 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	53.5% 23/43 • Number of events 89 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	68.3% 28/41 • Number of events 216 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Platelet count decreased	8.2% 31/376 • Number of events 56 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.2% 38/373 • Number of events 63 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.5% 51/378 • Number of events 98 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 19/153 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	47.5% 19/40 • Number of events 65 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	48.8% 21/43 • Number of events 56 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	61.0% 25/41 • Number of events 101 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Protein urine present	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Urinary occult blood positive	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.0% 8/40 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.2% 5/41 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Urine analysis abnormal	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Weight decreased	4.3% 16/376 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/373 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/378 • Number of events 19 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.6% 7/153 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.3% 10/43 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 9/41 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations Weight increased	2.1% 8/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/373 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	40.0% 16/40 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	41.9% 18/43 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations White blood cell count decreased	10.1% 38/376 • Number of events 74 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.5% 39/373 • Number of events 82 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 53/378 • Number of events 122 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.5% 16/153 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	60.0% 24/40 • Number of events 69 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	58.1% 25/43 • Number of events 94 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	65.9% 27/41 • Number of events 150 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Investigations White blood cells urine positive	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 27 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Decreased appetite	11.4% 43/376 • Number of events 53 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.7% 51/373 • Number of events 66 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.2% 65/378 • Number of events 88 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.3% 25/153 • Number of events 33 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.0% 10/40 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.6% 11/43 • Number of events 37 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	34.1% 14/41 • Number of events 33 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypercholesterolaemia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.1% 4/378 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hyperglycaemia	3.7% 14/376 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/373 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.9% 6/153 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypertriglyceridaemia	1.3% 5/376 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.80% 3/373 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hyperuricaemia	1.3% 5/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.6% 8/43 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypoalbuminaemia	2.1% 8/376 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/373 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	27.5% 11/40 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	34.9% 15/43 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 11/41 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypocalcaemia	0.80% 3/376 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.6% 4/153 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypokalaemia	4.8% 18/376 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/373 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/378 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 11/153 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.5% 7/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.6% 11/43 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypomagnesaemia	4.3% 16/376 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.6% 17/373 • Number of events 19 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.2% 12/378 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.5% 10/153 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hyponatraemia	3.7% 14/376 • Number of events 19 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.6% 21/373 • Number of events 27 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Metabolism and nutrition disorders Hypoproteinaemia	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Arthralgia	33.8% 127/376 • Number of events 198 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	34.6% 129/373 • Number of events 191 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	37.6% 142/378 • Number of events 201 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	33.3% 51/153 • Number of events 79 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.0% 10/40 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.6% 8/43 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 9/41 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Back pain	12.0% 45/376 • Number of events 49 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.9% 37/373 • Number of events 41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.1% 38/378 • Number of events 45 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 19/153 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Muscle spasms	3.2% 12/376 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.9% 11/373 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.3% 20/378 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.5% 10/153 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Myalgia	20.2% 76/376 • Number of events 105 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	21.7% 81/373 • Number of events 114 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.3% 69/378 • Number of events 120 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.9% 32/153 • Number of events 52 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.3% 10/43 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	24.4% 10/41 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Musculoskeletal and connective tissue disorders Pain in extremity	6.9% 26/376 • Number of events 35 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.1% 34/373 • Number of events 40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.4% 43/378 • Number of events 62 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.5% 13/153 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.1% 7/41 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Sinus bradycardia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Sinus tachycardia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.54% 2/373 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.26% 1/378 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.65% 1/153 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Dizziness	8.5% 32/376 • Number of events 41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 26/373 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.5% 36/378 • Number of events 51 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.5% 13/153 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Dysgeusia	5.6% 21/376 • Number of events 27 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.4% 24/373 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.4% 28/378 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.5% 16/153 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Cardiac disorders Supraventricular extrasystoles	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/373 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Headache	20.7% 78/376 • Number of events 113 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.1% 75/373 • Number of events 108 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 83/378 • Number of events 122 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.0% 26/153 • Number of events 42 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Hypoaesthesia	0.27% 1/376 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.6% 6/378 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.0% 12/40 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	27.9% 12/43 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	48.8% 20/41 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Neuropathy peripheral	15.4% 58/376 • Number of events 64 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.4% 61/373 • Number of events 69 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	16.9% 64/378 • Number of events 77 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.1% 20/153 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Paraesthesia	8.0% 30/376 • Number of events 33 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.8% 29/373 • Number of events 32 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.4% 28/378 • Number of events 33 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 9/153 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Peripheral sensory neuropathy	15.2% 57/376 • Number of events 66 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.7% 55/373 • Number of events 61 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.7% 67/378 • Number of events 77 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	17.0% 26/153 • Number of events 26 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Nervous system disorders Polyneuropathy	9.0% 34/376 • Number of events 37 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.8% 29/373 • Number of events 32 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.7% 33/378 • Number of events 35 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 11/153 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Psychiatric disorders Insomnia	9.3% 35/376 • Number of events 40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 28/373 • Number of events 31 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.7% 29/378 • Number of events 37 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.1% 17/153 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Haematuria	2.9% 11/376 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 5/373 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.1% 8/378 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Renal and urinary disorders Proteinuria	12.5% 47/376 • Number of events 64 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.7% 40/373 • Number of events 51 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.1% 23/378 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	8.5% 13/153 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	40.0% 16/40 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	32.6% 14/43 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	41.5% 17/41 • Number of events 33 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Cough	6.1% 23/376 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.7% 36/373 • Number of events 43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.8% 41/378 • Number of events 49 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 11/153 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.3% 4/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Dysphonia	5.3% 20/376 • Number of events 22 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.4% 24/373 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 19/378 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.9% 6/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	11.7% 44/376 • Number of events 57 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	13.9% 52/373 • Number of events 63 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.9% 45/378 • Number of events 58 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.2% 11/153 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	14.9% 56/376 • Number of events 65 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.5% 43/373 • Number of events 54 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 47/378 • Number of events 65 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 19/153 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Alopecia	21.0% 79/376 • Number of events 79 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.6% 88/373 • Number of events 91 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.2% 99/378 • Number of events 104 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.3% 28/153 • Number of events 30 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.0% 10/40 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.9% 9/43 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Dry skin	2.9% 11/376 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.5% 13/373 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.3% 20/378 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.3% 5/153 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Pruritus	9.6% 36/376 • Number of events 45 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.5% 58/373 • Number of events 76 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 47/378 • Number of events 58 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 19/153 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.6% 11/43 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Skin and subcutaneous tissue disorders Rash	7.7% 29/376 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.6% 47/373 • Number of events 59 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.4% 47/378 • Number of events 62 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 15/153 • Number of events 21 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.0% 2/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.9% 9/43 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	19.5% 8/41 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Hot flush	4.3% 16/376 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.5% 13/373 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.3% 20/378 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.3% 5/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.3% 1/43 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Vascular disorders Hypertension	33.0% 124/376 • Number of events 146 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.3% 113/373 • Number of events 143 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.9% 98/378 • Number of events 121 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.9% 32/153 • Number of events 47 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	32.5% 13/40 • Number of events 15 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 6/43 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.6% 6/41 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Hyperthyroidism	2.1% 8/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.5% 43/373 • Number of events 49 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.6% 25/378 • Number of events 32 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	6.5% 10/153 • Number of events 11 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.3% 3/41 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Endocrine disorders Hypothyroidism	6.9% 26/376 • Number of events 28 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	21.2% 79/373 • Number of events 93 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	20.4% 77/378 • Number of events 89 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.5% 36/153 • Number of events 40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.5% 5/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.6% 8/43 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	39.0% 16/41 • Number of events 36 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal discomfort	2.1% 8/376 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/373 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 9/378 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.0% 3/153 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal distension	2.7% 10/376 • Number of events 10 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.0% 15/373 • Number of events 16 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.4% 13/378 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.9% 6/153 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.0% 3/43 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	12.2% 5/41 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal pain	17.8% 67/376 • Number of events 84 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 82/373 • Number of events 103 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.0% 83/378 • Number of events 116 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 23/153 • Number of events 31 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	15.0% 6/40 • Number of events 6 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	18.6% 8/43 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 11/41 • Number of events 18 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Abdominal pain upper	10.4% 39/376 • Number of events 51 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.9% 37/373 • Number of events 44 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	14.0% 53/378 • Number of events 70 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.8% 18/153 • Number of events 24 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 5 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	11.6% 5/43 • Number of events 8 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	9.8% 4/41 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Constipation	24.7% 93/376 • Number of events 133 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	24.9% 93/373 • Number of events 136 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	31.0% 117/378 • Number of events 193 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.5% 36/153 • Number of events 52 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	27.5% 11/40 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	25.6% 11/43 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	24.4% 10/41 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Diarrhoea	29.0% 109/376 • Number of events 164 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	30.0% 112/373 • Number of events 177 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	29.1% 110/378 • Number of events 197 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	24.2% 37/153 • Number of events 64 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	22.5% 9/40 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	23.3% 10/43 • Number of events 13 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	26.8% 11/41 • Number of events 23 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Dry mouth	0.53% 2/376 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.4% 20/373 • Number of events 20 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.4% 13/378 • Number of events 14 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.3% 2/153 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/40 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Dyspepsia	5.3% 20/376 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.9% 22/373 • Number of events 25 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.9% 30/378 • Number of events 34 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	5.2% 8/153 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.5% 1/40 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/41 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Functional gastrointestinal disorder	0.00% 0/376 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.27% 1/373 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/378 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/153 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	7.5% 3/40 • Number of events 3 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	0.00% 0/43 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	2.4% 1/41 • Number of events 1 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.
Gastrointestinal disorders Gingival bleeding	2.9% 11/376 • Number of events 12 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	1.9% 7/373 • Number of events 7 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	3.7% 14/378 • Number of events 17 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.6% 7/153 • Number of events 9 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	10.0% 4/40 • Number of events 4 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.7% 2/43 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.	4.9% 2/41 • Number of events 2 • For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months. Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment.

Additional Information

Global Clinical Lead

AstraZeneca Clinical Study Information Center

Phone: 1-877-240-9479

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place